Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2010 Jun 10;28(17):2853-8.
doi: 10.1200/JCO.2009.26.5827. Epub 2010 May 3.

Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study

Marinus H J van Oers  1 , Martine Van Glabbeke, Livia Giurgea, Richard Klasa, Robert E Marcus, Max Wolf, Eva Kimby, Mars van t Veer, Andrej Vranovsky, Harald Holte, Anton Hagenbeek
Affiliations
Clinical Trial

Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study

Marinus H J van Oers et al. J Clin Oncol. .

Abstract

Purpose: In 2006, we published the results of the European Organisation for Research and Treatment of Cancer phase III trial EORTC 20981 on the role of rituximab in remission induction and maintenance treatment of relapsed/resistant follicular lymphoma (FL). At that time, the median follow-up for the maintenance phase was 33 months. Now, we report the long-term outcome of maintenance treatment, with a median follow-up of 6 years.

Patients and methods: Overall, 465 patients were randomly assigned to induction with either six cycles of cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or rituximab plus CHOP (R-CHOP). Those in complete remission or partial remission after induction (n = 334) were randomly assigned to maintenance treatment with rituximab (375 mg/m(2) intravenously once every 3 months) or observation.

Results: Rituximab maintenance significantly improved progression-free survival (PFS) compared with observation (median, 3.7 years v 1.3 years; P < .001; hazard ratio [HR], 0.55), both after CHOP induction (P < .001; HR, 0.37) and R-CHOP (P = .003; HR, 0.69). The 5-year overall survival (OS) was 74% in the rituximab maintenance arm, and it was 64% in the observation arm (P = .07). After progression, a rituximab-containing salvage therapy was given to 59% of patients treated with CHOP followed by observation, compared with 26% after R-CHOP followed by rituximab maintenance. Rituximab maintenance was associated with a significant increase in grades 3 to 4 infections: 9.7% v 2.4% (P = .01).

Conclusion: With long-term follow-up, we confirm the superior PFS with rituximab maintenance in relapsed/resistant FL. The improvement of OS did not reach statistical significance, possibly because of the unbalanced use of rituximab in post-protocol salvage treatment.

PubMed Disclaimer

Conflict of interest statement

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Figures

Fig 1.
Fig 1.
CONSORT diagram of (A) all randomly allocated patients and (B) those randomly assigned to maintenance. CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; R-CHOP, rituximab plus CHOP; CR, complete remission; PR, partial remission; PD, progressive disease.
Fig 2.
Fig 2.
Effect of rituximab maintenance treatment on progression-free survival (PFS). Kaplan-Meier plot of PFS from second random assignment after rituximab maintenance therapy (n = 167) and observation (n = 167). Rituximab maintenance, median 3.7 years; observation, median 1.3 years. HR, hazard ratio.
Fig 3.
Fig 3.
Effect of rituximab maintenance treatment on progression-free survival (PFS) after remission induction with either cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or rituximab plus CHOP (R-CHOP). Kaplan-Meier plots of PFS and overall survival from second random assignment. (A) PFS after CHOP remission induction (n = 145). Rituximab maintenance, median 3.1 years; observation, median 1.0 year. (B) PFS after R-CHOP remission induction (n = 189). Rituximab maintenance, median 4.4 years; observation, median 1.9 years. HR, hazard ratio; O, observed; N, number.
Fig 4.
Fig 4.
Effect of rituximab maintenance treatment on progression-free survival (PFS) in patients in partial remission (PR) or complete remission (CR) after remission induction treatment. Kaplan-Meier plots of PFS and overall survival from second random assignment. (A) PFS in patients with PR (n = 237). Rituximab maintenance, median 3.4 years; observation, median 1.3 years. (B) PFS in patients with CR (n = 97). Rituximab maintenance, median 4.4 years; observation, median 1.2 years. HR, hazard ratio; O, observed; N, number.
Fig 5.
Fig 5.
Effect of rituximab maintenance treatment on overall survival. Kaplan-Meier plot of overall survival from second random assignment after rituximab maintenance therapy (n = 167) and observation (n = 167). Rituximab maintenance, 74.3% at 5 years; observation, 64.7% at 5 years. HR, hazard ratio.
See this image and copyright information in PMC

References

    1. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:3725–3732. - PubMed
    1. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105:1417–1423. - PubMed
    1. Salles G, Mounier N, de Guibert S, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: Results of the GELA-GOELAMS FL2000 study. Blood. 2008;112:4824–4831. - PubMed
    1. Herold M, Haas A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An East German Study Group Hematology and Oncology Study. J Clin Oncol. 2007;25:1986–1992. - PubMed
    1. van Oers MH. Rituximab maintenance therapy: A step forward in follicular lymphoma. Haematologica. 2007;92:826–833. - PubMed

Publication types

MeSH terms

Supplementary concepts